SCHEMBL2089381

SCHEMBL2089381

Cc1ccc(OC=O)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 3/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14363845 0.84 ACHE (0.48) ACHECA1CA2CA9L3MBTL1
SCHEMBL27759238 0.83 ACHE (0.39) ACHECA1CA2CA9L3MBTL1
SCHEMBL97154 0.83 TSHR (0.44) ACHECA1CA2CA9SMN1; SMN2
SCHEMBL16253390 0.80 GAA (0.40) ACHECA1CA2CA9SMN1; SMN2
SCHEMBL10627302 0.80 ACHE (0.43) ACHECA1CA2CA9L3MBTL1
SCHEMBL23457804 0.79 ACHE (0.65) ACHEL3MBTL1SMN1; SMN2HPGDKMT2A
SCHEMBL5542388 0.79 ALDH1A1 (0.48) CA1CA2CA9L3MBTL1KMT2A
SCHEMBL14864481 0.79 MRGPRX4 (0.40) ACHECA1CA2CA9MAPK1
SCHEMBL18348326 0.79 KDM4E (0.42) L3MBTL1SMN1; SMN2HPGDKMT2ATSHR
SCHEMBL12121021 0.79 ACHE (0.43) ACHECA1CA2CA9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0354297-B1 THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-08-05 EP claimed
US-20240018174-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MED SYST INC (US) 2024-01-18 US disclosed
US-11780863-B2 Quinone methide analog signal amplification VENTANA MEDICAL SYSTEMS, INC. (US) 2023-10-10 US disclosed
WO-2023072237-A1 ZSM-5 MOLECULAR SIEVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, HYDROTREATMENT CATALYST, HYDRODEWAXING CATALYST, AND APPLICATIONS THEREOF 中国石油化工股份有限公司 2023-05-04 WO disclosed
US-20170089911-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MEDICAL SYSTEMS, INC. 2017-03-30 US disclosed
US-9608287-B2 Non-aqueous electrolytic solution, electrical storage device utilizing same, and cyclic sulfonic acid ester compound UBE INDUSTRIES, LTD. (JP) 2017-03-28 US disclosed
CN-105873889-A Process for the purification of crude product to produce terephthalic acid using dehydration column condensate BP北美公司 2016-08-17 CN disclosed
CN-102239000-B Systems and methods for managing reactor transients INVISTA TECH SARL 2014-09-24 CN disclosed
EP-2704246-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTRICAL STORAGE DEVICE UTILIZING SAME, AND CYCLIC SULFONIC ACID ESTER COMPOUND Ube Industries, Ltd. (JP) 2014-03-05 EP disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-0310214-A2 7-Substituted bicyclic pyrazolidinones ELI LILLY AND COMPANY (US) 1989-04-05 EP disclosed
US-4795815-A BACTERICIDES, MICROBIOCIDES ELI LILLY AND COMPANY (US) 1989-01-03 US disclosed
US-4716232-A 1-(vinyl phosphonate adduct) pyrazolidinones ELI LILLY AND COMPANY (US) 1987-12-29 US disclosed
EP-0203722-A1 Bicyclic pyrazolidinones ELI LILLY AND COMPANY (US) 1986-12-03 EP disclosed
EP-0203723-A1 2,3-(dihydro)bicyclic pyrazolidinones ELI LILLY AND COMPANY (US) 1986-12-03 EP disclosed
EP-0202794-A1 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones ELI LILLY AND COMPANY (US) 1986-11-26 EP disclosed
EP-0202046-A1 7-Substituted bicyclic pyrazolidinones ELI LILLY AND COMPANY (US) 1986-11-20 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed
US-4259350-A PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK SANKYO COMPANY LIMITED (JP) 1981-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780863-B2 Quinone methide analog signal amplification NQO2, SQOR, MRM1 ACHE 67/4885CA1 1613/4885CA2 2563/4885
US-20240018174-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION NQO2, SQOR, MRM1 ACHE 67/4885CA1 1613/4885CA2 2563/4885
US-20170089911-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION NQO2, SQOR, MRM1 ACHE 67/4885CA1 1613/4885CA2 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.